DK1599469T3 - Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed - Google Patents
Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermedInfo
- Publication number
- DK1599469T3 DK1599469T3 DK04818324T DK04818324T DK1599469T3 DK 1599469 T3 DK1599469 T3 DK 1599469T3 DK 04818324 T DK04818324 T DK 04818324T DK 04818324 T DK04818324 T DK 04818324T DK 1599469 T3 DK1599469 T3 DK 1599469T3
- Authority
- DK
- Denmark
- Prior art keywords
- methods
- related disorders
- tetrazole derivatives
- treating metabolism
- metabolism
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51623803P | 2003-10-31 | 2003-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1599469T3 true DK1599469T3 (da) | 2006-10-09 |
Family
ID=34572875
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04818324T DK1599469T3 (da) | 2003-10-31 | 2004-10-29 | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US8637555B2 (de) |
| EP (2) | EP1683794A1 (de) |
| JP (2) | JP4533898B2 (de) |
| KR (1) | KR100850591B1 (de) |
| CN (1) | CN1867562B (de) |
| AR (1) | AR046611A1 (de) |
| AT (1) | ATE328880T1 (de) |
| AU (1) | AU2004287861B2 (de) |
| BR (1) | BRPI0415631A (de) |
| CA (1) | CA2539985C (de) |
| CO (1) | CO5690551A2 (de) |
| CR (1) | CR8270A (de) |
| CY (1) | CY1105479T1 (de) |
| DE (1) | DE602004001134T2 (de) |
| DK (1) | DK1599469T3 (de) |
| EA (1) | EA011484B1 (de) |
| EC (1) | ECSP066529A (de) |
| ES (1) | ES2267077T3 (de) |
| GE (1) | GEP20094801B (de) |
| HK (1) | HK1076468A1 (de) |
| HR (1) | HRP20060286T3 (de) |
| IL (1) | IL174042A0 (de) |
| IS (1) | IS2372B (de) |
| MA (1) | MA28171A1 (de) |
| MX (1) | MXPA06004556A (de) |
| MY (1) | MY140410A (de) |
| NO (1) | NO20062509L (de) |
| NZ (1) | NZ546285A (de) |
| PE (1) | PE20050483A1 (de) |
| PL (1) | PL1599469T3 (de) |
| PT (1) | PT1599469E (de) |
| RS (1) | RS20060290A (de) |
| SI (1) | SI1599469T1 (de) |
| TN (1) | TNSN06150A1 (de) |
| TW (1) | TWI258478B (de) |
| UA (1) | UA86783C2 (de) |
| WO (1) | WO2005044816A1 (de) |
| ZA (2) | ZA200603419B (de) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| DE602004022864D1 (de) * | 2003-11-21 | 2009-10-08 | Arena Pharm Inc | 4-oxo-4,5-dihydro-furan-2-carbonsäure und derivate und verfahren zur behandlung von stoffwechselerkrankungen mit diesen verbindungen |
| US20070244107A1 (en) * | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20080139628A1 (en) * | 2004-11-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006114581A1 (en) * | 2005-04-28 | 2006-11-02 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
| US8168649B2 (en) | 2005-06-28 | 2012-05-01 | Merk Sharp & Dohme Corp. | Niacin receptor agonists, compositions containing such compounds and methods of treatment |
| DE102006021733A1 (de) * | 2006-05-09 | 2007-11-22 | Bayer Healthcare Ag | 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung |
| DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
| DE102008063992A1 (de) | 2008-12-19 | 2010-09-02 | Lerner, Zinoviy, Dipl.-Ing. | Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| AR091739A1 (es) | 2012-07-11 | 2015-02-25 | Elcelyx Therapeutics Inc | Composiciones y metodos para reducir el riesgo cardiometabolico |
| KR20150119871A (ko) | 2013-02-21 | 2015-10-26 | 아드베리오 파마 게엠베하 | 메틸 ｛4,6-디아미노-2-[1-(2-플루오로벤질)-1H-피라졸로[3,4-b]피리디노-3-일]피리미디노-5-일｝메틸 카르바메이트의 형태 |
| US9975910B2 (en) | 2013-07-23 | 2018-05-22 | Eisai R&D Management Co., Ltd. | Hetero-fused cyclic compound |
| CN103755637A (zh) * | 2013-12-26 | 2014-04-30 | 平湖优康药物研发有限公司 | 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺 |
| US12086719B2 (en) * | 2019-10-11 | 2024-09-10 | Royal Bank Of Canada | System and method of machine learning using embedding networks |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02178263A (ja) * | 1988-12-27 | 1990-07-11 | Kaken Pharmaceut Co Ltd | アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤 |
| US5134155A (en) * | 1991-08-08 | 1992-07-28 | Ortho Pharmaceutical Corporation | Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors |
| US5948786A (en) | 1996-04-12 | 1999-09-07 | Sumitomo Pharmaceuticals Company, Limited | Piperidinylpyrimidine derivatives |
| EP0946508B1 (de) | 1996-12-23 | 2009-09-23 | Bristol-Myers Squibb Pharma Company | Stickstoffhaltige heterocyclen als faktor xa-hemmer |
| ATE451346T1 (de) | 1998-03-10 | 2009-12-15 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| US6414002B1 (en) | 1999-09-22 | 2002-07-02 | Bristol-Myers Squibb Company | Substituted acid derivatives useful as antidiabetic and antiobesity agents and method |
| MXPA02008801A (es) | 2000-03-09 | 2003-07-07 | Ono Pharmaceutical Co | Derivados de indol, proceso para la preparacion de los mismos y su uso. |
| US20010047027A1 (en) | 2000-04-12 | 2001-11-29 | Marc Labelle | Prostaglandin D2 receptor antagonists |
| MXPA02012795A (es) | 2000-06-28 | 2004-07-30 | Teva Pharma | Carvedilol. |
| CA2413134C (en) | 2000-06-30 | 2010-05-11 | Glaxo Group Limited | Quinazoline ditosylate salt compounds |
| US6410583B1 (en) | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| DE10057751A1 (de) | 2000-11-22 | 2002-05-23 | Bayer Ag | Neue Carbamat-substituierte Pyrazolopyridinderivate |
| JP4279561B2 (ja) | 2001-05-23 | 2009-06-17 | メルク フロスト カナダ リミテツド | プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体 |
| WO2002098864A1 (en) | 2001-06-01 | 2002-12-12 | F. Hoffmann-La Roche Ag | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
| US20030139435A1 (en) | 2001-06-26 | 2003-07-24 | Gulzar Ahmed | N-heterocyclic inhibitors of TNF-alpha expression |
| EP1292602B1 (de) | 2001-06-27 | 2004-04-07 | RS Tech Corp. | Neuer chiraler salen-katalysator und verfahren zur herstellung chiraler verbindungen aus racemischen epoxiden unter verwendung des neuen katalysators |
| KR20040044856A (ko) | 2001-09-07 | 2004-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체 화합물 |
| DE10148617A1 (de) | 2001-09-25 | 2003-04-24 | Schering Ag | Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel |
| AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
| IL164094A0 (en) | 2002-03-19 | 2005-12-18 | Ono Pharmaceutical Co | Carboxyoic acid compounds and drugs containing thecompounds as the active ingredient |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| AU2003282679A1 (en) | 2002-10-04 | 2004-05-04 | Arena Pharmaceuticals, Inc. | Hydroxypyrazoles for use against metabolic-related disorders |
| AU2003300014A1 (en) * | 2002-10-10 | 2004-05-04 | Arena Pharmaceuticals, Inc. | 5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia |
| DE10261131A1 (de) | 2002-12-20 | 2004-07-01 | Grünenthal GmbH | Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| AR041089A1 (es) | 2003-05-15 | 2005-05-04 | Merck & Co Inc | Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas |
| US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
| AU2004260636A1 (en) | 2003-06-13 | 2005-02-10 | Arena Pharmaceuticals, Inc. | 5-substituted 2H-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor RUP25 for the treatment of dyslipidemia and related diseases |
| GB0319124D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| GB0319126D0 (en) | 2003-08-14 | 2003-09-17 | Smithkline Beecham Corp | Chemical compounds |
| PE20050483A1 (es) | 2003-10-31 | 2005-08-25 | Arena Pharm Inc | Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas |
| PT1781657E (pt) | 2004-02-14 | 2013-05-23 | Glaxosmithkline Ip Dev Ltd | Medicamentos com actividade no receptor hm74a |
| US20070244107A1 (en) | 2004-08-25 | 2007-10-18 | Waters M Gerard | Method of Treating Atherosclerosis, Dyslipidemias and Related Conditions |
| US20080139628A1 (en) | 2004-11-05 | 2008-06-12 | Arena Pharmaceuticals, Inc. | Compositions For Treating Flushing And Lipid-Associated Disorders Comprising Niacin Receptor Partial Agonists |
| PE20060949A1 (es) | 2004-12-23 | 2006-10-11 | Arena Pharm Inc | Derivados fusionados de pirazol como agonistas del receptor de niacina |
| WO2006114581A1 (en) | 2005-04-28 | 2006-11-02 | Merck Sharp & Dohme Limited | A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles |
-
2004
- 2004-10-27 PE PE2004001031A patent/PE20050483A1/es not_active Application Discontinuation
- 2004-10-27 TW TW093132486A patent/TWI258478B/zh not_active IP Right Cessation
- 2004-10-28 MY MYPI20044462A patent/MY140410A/en unknown
- 2004-10-29 KR KR1020067008311A patent/KR100850591B1/ko not_active IP Right Cessation
- 2004-10-29 SI SI200430058T patent/SI1599469T1/sl unknown
- 2004-10-29 EP EP06005248A patent/EP1683794A1/de not_active Withdrawn
- 2004-10-29 NZ NZ546285A patent/NZ546285A/en not_active IP Right Cessation
- 2004-10-29 RS YUP-2006/0290A patent/RS20060290A/sr unknown
- 2004-10-29 AT AT04818324T patent/ATE328880T1/de active
- 2004-10-29 CN CN2004800299376A patent/CN1867562B/zh not_active Expired - Fee Related
- 2004-10-29 EP EP04818324A patent/EP1599469B1/de not_active Expired - Lifetime
- 2004-10-29 CA CA2539985A patent/CA2539985C/en not_active Expired - Fee Related
- 2004-10-29 US US10/535,345 patent/US8637555B2/en not_active Expired - Fee Related
- 2004-10-29 JP JP2006536942A patent/JP4533898B2/ja not_active Expired - Fee Related
- 2004-10-29 WO PCT/US2004/035927 patent/WO2005044816A1/en active IP Right Grant
- 2004-10-29 PL PL04818324T patent/PL1599469T3/pl unknown
- 2004-10-29 UA UAA200605989A patent/UA86783C2/ru unknown
- 2004-10-29 BR BRPI0415631-5A patent/BRPI0415631A/pt not_active IP Right Cessation
- 2004-10-29 AU AU2004287861A patent/AU2004287861B2/en not_active Ceased
- 2004-10-29 AR ARP040103978A patent/AR046611A1/es unknown
- 2004-10-29 GE GEAP20049421A patent/GEP20094801B/en unknown
- 2004-10-29 ES ES04818324T patent/ES2267077T3/es not_active Expired - Lifetime
- 2004-10-29 MX MXPA06004556A patent/MXPA06004556A/es active IP Right Grant
- 2004-10-29 EA EA200600879A patent/EA011484B1/ru not_active IP Right Cessation
- 2004-10-29 DE DE602004001134T patent/DE602004001134T2/de not_active Expired - Lifetime
- 2004-10-29 PT PT04818324T patent/PT1599469E/pt unknown
- 2004-10-29 DK DK04818324T patent/DK1599469T3/da active
-
2005
- 2005-12-06 HK HK05111162A patent/HK1076468A1/xx not_active IP Right Cessation
-
2006
- 2006-03-01 IL IL174042A patent/IL174042A0/en unknown
- 2006-03-03 CR CR8270A patent/CR8270A/es not_active Application Discontinuation
- 2006-03-30 CO CO06031620A patent/CO5690551A2/es not_active Application Discontinuation
- 2006-04-28 ZA ZA200603419A patent/ZA200603419B/en unknown
- 2006-04-28 EC EC2006006529A patent/ECSP066529A/es unknown
- 2006-05-22 TN TNP2006000150A patent/TNSN06150A1/en unknown
- 2006-05-23 MA MA29049A patent/MA28171A1/fr unknown
- 2006-05-24 IS IS8481A patent/IS2372B/is unknown
- 2006-05-31 NO NO20062509A patent/NO20062509L/no not_active Application Discontinuation
- 2006-07-26 ZA ZA200606203A patent/ZA200606203B/xx unknown
- 2006-08-24 HR HR20060286T patent/HRP20060286T3/xx unknown
- 2006-09-05 CY CY20061101259T patent/CY1105479T1/el unknown
- 2006-11-17 US US11/601,252 patent/US20070072924A1/en not_active Abandoned
-
2010
- 2010-03-10 JP JP2010053852A patent/JP2010163448A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20055211D0 (no) | Anti-fungale forbindelser og fremgangsmater for anvendelse | |
| DK1644021T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme | |
| IS7977A (is) | Samsetningar og aðferð til samsettra meðferðar | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| DK1592686T3 (da) | Gyrase-inhibitorer og anvendelser deraf | |
| DK1824475T3 (da) | Fremgangsmåde til oprensning af trans-(-)-delta9-tetrahydrocannabinol og trans-(+)-delta9-tetrahydrocannabinol | |
| DK1997809T3 (da) | P38-inhibitorer og fremgangsmåder til anvendelse deraf | |
| IS8037A (is) | P38-hindrar og aðferðir til notkunar þeirra | |
| DK1805312T3 (da) | Fremgangsmåder og midler til fremstilling af hyaluronan | |
| DK1663978T3 (da) | Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser | |
| DK1830838T3 (da) | Sammensætninger og fremgangsmåder til behandling af neoplastiske sygdomme | |
| DK1673104T4 (da) | Fremføring af terapeutiske forbindelser til hjernen og andre væv | |
| DK1706112T3 (da) | Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom | |
| DK1891571T3 (da) | Hæmning af spredning af uønskede koder og data | |
| DK1803718T3 (da) | 4-Tetrazolyl-4-phenylpiperidin-derivater til behandling af smerter | |
| DK1701944T3 (da) | 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme | |
| DE602005001520D1 (de) | Zeiteinstellungssystem und Zeiteinstellungsverfahren | |
| DK1997512T3 (da) | Fremgangsmåder til behandling af TWEAK-relaterede tilstande | |
| DK1599469T3 (da) | Tetrazolderivater og fremgangsmåder til behandling af metabolismerelaterede forstyrrelser dermed | |
| NO20053874D0 (no) | Formulering og metoder for behandling av thrombocytemi | |
| DK1750713T3 (da) | Anvendelse af imatinib til behandling af leversygdomme og vi-rusinfektioner | |
| DK1611890T3 (da) | Fremgangsmåde til evaluering og behandling af cancer | |
| IS8497A (is) | Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma | |
| DK1667730T3 (da) | Sammensætninger og fremgangsmåder til behandling af inflammatorisk lungesygdom | |
| DK1596868T3 (da) | Fremgangsmåde til behandling af hjertesvigt og medikament dertil |